Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.

ABSTRACT:

Objective

To examine the association between dipeptidyl peptidase-4 inhibitors and gallbladder or biliary diseases.

Design

Systematic review and pairwise and network meta-analysis.

Data sources

PubMed, EMBASE, Web of Science, and CENTRAL from inception until 31 July 2021.

Eligibility criteria

Randomised controlled trials of adult patients with type 2 diabetes who received dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors compared with placebo or other antidiabetes drugs.

Main outcome measures

Composite of gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases.

Data extraction and data synthesis

Two reviewers independently extracted the data and

SUBMITTER: He L 

PROVIDER: S-EPMC9237836 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature